Higher Irradiance in Keratoconus Ectasia
| Status: | Recruiting |
|---|---|
| Conditions: | Ocular, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Ophthalmology |
| Healthy: | No |
| Age Range: | 16 - Any |
| Updated: | 10/1/2017 |
| Start Date: | August 2010 |
| End Date: | December 30, 2018 |
| Contact: | MaEdylin Bautista |
| Email: | mmb2225@columbia.edu |
| Phone: | 212-305-5922 |
Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross- Linking at Higher Irradiances in Patients With Keratoconus or Ectasia
The purpose of the study is to see if brighter lights will allow for shortening of the
treatment time required to stabilize the eyes of patients with keratoconus or a bulging
cornea. The investigators will be comparing the therapeutic effects of two different higher
brightnesses of ultra violet light on a riboflavin treated eye. One light will be twice as
bright as the other and the exposure time of these brighter lights to deliver equivalent
energy to the cornea will be reduced from the standard 30 minutes to 10 and 5 minutes.
Riboflavin is vitamin B2 and the investigators are trying to determine if an identical
clinical effect can be achieved the brighter treatment lights are used for shorter times. The
investigators will also monitor the clinical effect and the status of the cornea to see if
additional risks are associated with the brighter light.
treatment time required to stabilize the eyes of patients with keratoconus or a bulging
cornea. The investigators will be comparing the therapeutic effects of two different higher
brightnesses of ultra violet light on a riboflavin treated eye. One light will be twice as
bright as the other and the exposure time of these brighter lights to deliver equivalent
energy to the cornea will be reduced from the standard 30 minutes to 10 and 5 minutes.
Riboflavin is vitamin B2 and the investigators are trying to determine if an identical
clinical effect can be achieved the brighter treatment lights are used for shorter times. The
investigators will also monitor the clinical effect and the status of the cornea to see if
additional risks are associated with the brighter light.
Inclusion Criteria:
Subjects who have one or both eyes that meet two of the following criteria will be
considered candidates for this study:
1. 16 years of age or older
2. Having a diagnosis of progressive keratoconus or pellucid marginal degeneration.
1. Characteristic pattern of deformity as analyzed by the Pentacam map.
2. Minimal thickness of 350 microns
3. The ability to sign a written informed consent
4. States a willingness and ability to comply with schedule for follow-up visits
5. Subject willing to remove contact lenses prior to evaluation and treatment
Inclusion criteria for ectasia
1. History of having undergone a keratorefractive procedure and show:
1. Steepening by Pentacam study
2. Thinning of cornea
3. Shift in the position of thinnest portion of cornea
4. Unstable refraction with increasing myopia and astigmatism
5. Development of irregular astigmatism
2. At least two of the above criteria must be present.
Exclusion Criteria:
Subjects meeting any of the following criteria will be excluded from this study:
Subjects meeting any of the following criteria will be excluded from this protocol:
1. Eyes classified as either normal or atypical normal,
2. Corneal pachymetry ≤ 350 microns at the thinnest point in treatment zone measured by
Pentacam.
3. A history of delayed epithelial healing.
4. Pregnancy (including plan to become pregnant) or lactation during the course of the
study
5. A known sensitivity to study medications
6. Patients with nystagmus or any other condition that is severe enough to prevent steady
gaze during the treatment
7. Inability to cooperate with diagnostic tests.
8. Patients with a current condition that, in the investigator's opinion, would interfere
with or prolong epithelial healing.
9. Patients who are unable to remain supine and tolerate a lid speculum.
We found this trial at
1
site
New York, New York 10032
Principal Investigator: Stephen Trokel, MD
Phone: 212-305-5922
Click here to add this to my saved trials
